Compare Jabil Inc (JBL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Jabil Inc trades at $290 (market cap $33.31B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Jabil Inc is far larger — about 34.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Jabil Inc pays a 0.1% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 24 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JBL | MRVI | |
|---|---|---|
Market Cap | $33.31B | $972.90M |
Volume | 1,264,382 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $385.50 | $9.00 |
52-Week Low | $192.49 | $2.83 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $35.59B | $1.08B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $317.86, up 1.87% with strong technical momentum and bullish moving averages. The company delivered three consecutive earnings beats, with Q2 2026 EPS of $4.40 beating expectations of $4.07. Revenue growth is accelerating, with fiscal 2027 guidance projecting 24% growth driven by AI infrastructure demand. Analyst consensus remains strongly bullish with a $434.75 price target representing 37% upside potential.
The outlook remains positive with AI-driven growth catalysts and strong institutional support, though risks include execution challenges in scaling operations and market volatility despite strong fundamentals. Current valuation at 32.6 P/E appears reasonable given the growth trajectory, while the 74.11% ROE demonstrates exceptional capital efficiency.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
